These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 6294517)

  • 1. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].
    Trouillas P; Neuschwander P; Nighoghossian N; Adeleine P; Tremisi P
    Rev Neurol (Paris); 1989; 145(5):369-77. PubMed ID: 2662340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol.
    Stefoski D; Davis FA; Schauf CL
    Ann Neurol; 1985 Oct; 18(4):443-50. PubMed ID: 3000278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple sclerosis.
    McFarlin DE
    N Engl J Med; 1983 Jan; 308(4):215-7. PubMed ID: 6294519
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis].
    Watanabe T; Yamamoto T; Saito T; Sugano M; Tsukamoto T
    Rinsho Shinkeigaku; 1993 Jan; 33(1):15-20. PubMed ID: 8334769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IgG synthesis in the cerebrospinal fluid in patients with the chronic progressive phase of multiple sclerosis treated with cyclophosphamide and ACTH].
    Wender M; Michałowska G
    Neurol Neurochir Pol; 1986; 20(6):536-41. PubMed ID: 3037408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study.
    Glöckner WM; Sieberth HG; Wichmann HE; Backes E; Bambauer R; Boesken WH; Bohle A; Daul A; Graben N; Keller F
    Clin Nephrol; 1988 Jan; 29(1):1-8. PubMed ID: 3289804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy.
    Goodkin DE; Plencner S; Palmer-Saxerud J; Teetzen M; Hertsgaard D
    Arch Neurol; 1987 Aug; 44(8):823-7. PubMed ID: 2820359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
    Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
    Goodkin DE; Rudick RA; VanderBrug Medendorp S; Daughtry MM; Schwetz KM; Fischer J; Van Dyke C
    Ann Neurol; 1995 Jan; 37(1):30-40. PubMed ID: 7818255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathogenesis and treatment of multiple sclerosis. Review and personal results].
    Gérard JM; Hildebrand J; Mavroudakis N; Monseu G; Przedborski S; Seeldrayers P; Wautier J; Zegers de Beyl D
    Rev Med Brux; 1988 Sep; 9(6):334-9. PubMed ID: 2845554
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rapid modification of the symptomatology of progressive forms of multiple sclerosis by plasma exchange].
    Trouillas P; Neuschwander P; Trémisi JP
    Rev Neurol (Paris); 1986; 142(8-9):689-95. PubMed ID: 3809855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.